Phase I Trial of Motexafin Gadolinium (MGd) and Docetaxel Administered at 3-Week Intervals for Advanced Solid Tumors

Inclusion Criteria: * ≥ 18 years old * Histologically or cytologically confirmed diagnosis of cancer (i.e., Unresectable locally advanced or metastatic non-small-cell lung carcinoma (NSCLC) that had progressed during or after one or more chemotherapy regimens; Metastatic breast cancer; Hormone-refractory prostate cancer; Recurrent or refractory ovarian cancer; Sarcoma) * ECOG performance status score either 0 or 1 * Willing and able to provide written informed consent Exclusion Criteria: Laboratory Values of: * Absolute neutrophil count \< 2000/µL * Platelet count \< 100,00/µL * AST or ALT \> 1.5 x the upper limit of normal * Alkaline phosphatase \> 5 x the upper limit of normal * Bilirubin \> ULN * Creatinine \> 2.0 mg/dL and * Peripheral neuropathy NCI CTC Grade 3 or higher * Chemotherapy, radiation therapy, immunotherapy, or systemic biologic * anticancer therapy within 21 days before beginning study treatment * Known history of brain metastases or spinal cord compression * Uncontrolled hypertension * Myocardial infarction within 6 months before beginning study treatment * Unstable angina pectoris, uncontrolled congestive heart failure, or uncontrolled serious arrhythmias * Known sensitivity to or intolerable adverse effects from taxanes or polysorbate 80 * Known history of porphyria (testing not required at screening) * Known history of glucose-6-phosphate dehydrogenase (G6PD) deficiency (testing not required at screening) * Known history of HIV infection (testing not required at screening) * Female who is pregnant or lactating (pregnancy test is required for all female patients of childbearing potential) * Female of childbearing potential or sexually active male unwilling to use adequate contraceptive protection * Physical or mental condition that makes patient unable to complete specified follow-up assessments